Feng Zhang (R) with Aera Therapeutics CEO Akin Akinc (Aera)

'Rare out­lier­s': Feng Zhang eyes a new path to ge­net­ic med­i­cine de­liv­ery with ex-Al­ny­lam lead­ers and $193M

Mar­quee CRISPR sci­en­tist Feng Zhang, two-decade Al­ny­lam on­col­o­gy head Akin Ak­inc and sea­soned biotech gu­ru John Maraganore have come to­geth­er for a new bet on gene edit­ing, aim­ing to go be­yond the scope of the ex­ist­ing crop of clin­i­cal-stage tools.

They hope to de­liv­er big time — at­tempt­ing to up­end where po­ten­tial ther­a­peu­tic gold mines can go in the body, how they get shut­tled and the types of dis­eases the long-hyped ge­net­ic med­i­cine field can treat.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.